Yale University

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.

TitleDrug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.
Publication TypeJournal Article
Year of Publication2015
AuthorsDo, Albert, Yash Mittal, AnnMarie Liapakis, Elizabeth Cohen, Hong Chau, Claudia Bertuccio, Dana Sapir, Jessica Wright, Carol Eggers, Kristine Drozd, Maria Ciarleglio, Yanhong Deng, and Joseph K. Lim
JournalPloS one
Volume10
Issue8
Paginatione0135645
Date Published2015
ISSN1932-6203
AbstractNew treatments for hepatitis C (HCV) infection hold great promise for cure, but numerous challenges to diagnosing, establishing care, and receiving therapy exist. There are limited data on insurance authorization for these medications.
DOI10.1371/journal.pone.0135645
Alternate JournalPLoS ONE

External Links